BioTuesdays

Category - Markets

Eyenovia Logo
Markets

Analysts start Eyenovia at buy

Analysts for Ladenburg Thalmann and Roth Capital Partners initiated coverage of Eyenovia (NASDAQ:EYEN) with “buy” ratings and price targets of $35 and $20, respectively. The stock closed at $9 on Feb. 16. Eyenovia...

February 20, 2018
restorbio Logo
Markets

Leerink starts resTORbio at OP; PT $36

Leerink launched coverage of resTORbio (NASDAQ:TORC) with an “outperform” rating and $36 price target. The stock closed at $18.76 on Feb. 16. “Our rating and valuation are based on our sales forecast for lead asset...

February 20, 2018
Solid Biosciences
Markets

Leerink starts Solid Biosciences at OP; PT $36

Leerink initiated coverage of Solid Biosciences (NASDAQ:SLDB) with an “outperform” rating and $36 price target. The stock closed at $24.93 on Feb. 16. “We are encouraged by the preclinical data generated for...

February 20, 2018
Acer Therapeutics
Markets

WB starts Acer Therapeutics at OP; fair value $47

William Blair launched coverage of Acer Therapeutics (NASDAQ:ACER) with an “outperform” rating and fair value estimate of $47. The stock closed at $17 on Feb. 15. Acer is developing two late-stage clinical...

February 16, 2018
Quantum Genomics
Markets

Maxim halves Quantum Genomics PT to €6

Maxim Group slashed its price target for Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC) to €6 from €12, citing the company’s data through mid-2019. The stock closed at €2.75 on Feb. 14...

February 15, 2018
Galmed Logo
Markets

Maxim cuts Galmed Pharma to hold; removes PT

Maxim Group downgraded Galmed Pharmaceuticals (NASDAQ:GLMD) to “hold” from “buy” and removed its previous $14 price target after the company announced that top-line results from the ARRIVE trial...

February 14, 2018
Anavex
Markets

Maxim slashes PT for Anavex to $5 from $14

Maxim Group slashed its price target to Anavex Life Sciences (NASDAQ:AVXL) to $5 from $14, saying the company’s definitive proof-of-concept studies will take time and money. The stock closed at $2.54 on Feb. 13...

February 14, 2018
GlycoMimetics
Markets

Roth ups GlycoMimetics PT to $35

Roth Capital Partners raised its price target for GlycoMimetics (NASDAQ:GLYC) to $35 from $25 after the company agreed with the Dutch hematological oncology foundation, HOVON, to move towards a 140-patient study of GMI...

February 8, 2018
Conatus
Markets

Roth starts Conatus Pharma at buy; PT $20

Roth Capital Partners launched coverage of Conatus Pharmaceuticals (NASDAQ:CNAT) with a “buy” rating and $20 price target. The stock closed at $5.04 on Feb. 7. Conatus is a leader in the pan-caspase...

February 8, 2018